Sequenom, Inc. (NASDAQ: SQNM) designs, develops, manufactures and markets innovative technology, instrumentation and tests that target and serve discovery and clinical research, and clinical molecular diagnostics markets. Applications include translational research, oncology, agricultural genomics and in vitro diagnostics for prenatal and retinal disorders.
Technologies employed include mass spectrometry and second generation DNA sequencing. The company's proprietary MassARRAY® system is a high-performance mass spectrometry based DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations. The system delivers reliable and specific data from biological samples and from genetic target material that is only available in trace amounts.
The company was founded in 1994 and employs over 200 employees worldwide. Sequenom is headquartered in San Diego, CA.
Sequenom is committed to improving healthcare through revolutionary genetic analysis solutions.
No reviews to display
Targeted Mutation Profiling of Non-Small Cell Lung Cancer Samples using the Sequenom Lungcarta™ Panel for Clinical ResearchSequenom
30 May 2013
27 Oct 2011
29 Jun 2011